Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy： a meta-analysis

LI Jie; CHEN Xiaofei; XU Zihan; LIU Xiaoyan; ZHANG Yuechan; HAN Yi; ZHANG Wei; JIANG Zhitao

doi:10.6039/j.issn.1001-0408.2023.01.20

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy： a meta-analysis

更新时间：2023-02-22

- Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy： a meta-analysis
- ZHONGGUO YAOFANG Vol. 34, Issue 1, Pages: 102-106(2023)
- 作者机构：
  
  张家港市中医医院药学部，江苏张家港　215600
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.01.20
  CLC： R977.6
- Published：15 January 2023，
  
  Received：28 June 2022，
  
  Revised：12 October 2022，
扫描看全文
李杰,陈晓菲,徐子寒等.葡萄糖激酶激活剂治疗2型糖尿病有效性和安全性的Meta分析 ^Δ[J].中国药房,2023,34(01):102-106.

LI Jie,CHEN Xiaofei,XU Zihan,et al.Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy： a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(01):102-106.
李杰,陈晓菲,徐子寒等.葡萄糖激酶激活剂治疗2型糖尿病有效性和安全性的Meta分析 ^Δ[J].中国药房,2023,34(01):102-106. DOI： 10.6039/j.issn.1001-0408.2023.01.20.

LI Jie,CHEN Xiaofei,XU Zihan,et al.Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy： a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(01):102-106. DOI： 10.6039/j.issn.1001-0408.2023.01.20.

摘要

目的

系统评价葡萄糖激酶激活剂治疗2型糖尿病的有效性和安全性。

方法

检索PubMed、Cochrane Library、Web of Science、Embase、中国知网等数据库，时间为建库至2022年3月。纳入葡萄糖激酶激活剂与安慰剂（或其他口服降糖药）对照治疗2型糖尿病的随机对照试验，提取资料并用RevMan 5.4软件进行Meta分析。

结果

纳入9项研究，2 150名患者。降糖效果方面，与对照组相比，葡萄糖激酶激活剂能显著降低糖尿病患者糖化血红蛋白[MD＝－0.40，95%CI（－0.53，－0.26），

＜0.000 01]、空腹血糖[MD＝－0.53，95%CI（－0.85，－0.20），

＝0.001]和餐后2 h血糖[MD＝－2.28，95%CI（－2.68，－1.88），

＜0.000 01]。安全性方面，总体上葡萄糖激酶激活剂的低血糖发生率要高于对照组[RR＝1.55，95%CI（1.20，2.01），

＝0.000 8]；根据葡萄糖激酶激活剂激活的脏器进行亚组分析，胰腺肝脏双激活剂组[RR＝1.44，95%CI（1.11，1.89），

＝0.007]和肝脏选择性激活剂组[RR＝2.26，95%CI（1.02，5.03），

＝0.05]的低血糖发生率均要高于对照组，差异有统计学意义。

结论

葡萄糖激酶激活剂能有效降低2型糖尿病患者的糖化血红蛋白、空腹血糖及餐后2 h血糖，但其低血糖风险仍有待解决。

Abstract

OBJECTIVE

To systematically evaluate the efficacy and safety of glucokinase activators in the treatment of type 2 diabetes mellitus.

METHODS

PubMed， Cochrane Library， Web of Science， Embase and CNKI databases were searched from the inception to March 2022. Randomized controlled trials about glucokinase activators versus placebo （or other oral hypoglycemic agents） in the treatment of type 2 diabetes were included， data were extracted and meta-analysis was analyzed using RevMan 5.4 software.

RESULTS

A total of 9 studies with 215 0 patients were included. In terms of hypoglycemic effect， compared with control group， glucokinase activators significantly reduced glycosylated hemoglobin （HbA

c） [MD＝－0.40， 95%CI（－0.53，－0.26），

＜0.000 01]， fasting blood glucose[MD＝－0.53， 95%CI（－0.85，－0.20），

＝0.001] and 2 h postprandial blood glucose [MD＝－2.28， 95%CI（－2.68，－1.88），

＜0.000 01] in diabetic patients. In terms of safety， the incidence of hypoglycemia caused by glucokinase activators was higher than control group on the whole [RR＝1.55， 95%CI（1.20，2.01），

＝0.000 8]. According to the subgroup analysis of organs activated by glucokinas

e activator， the incidence of hypoglycemia in the pancreas-liver dual activator group [RR＝1.44， 95%CI（1.11，1.89），

＝0.007] and liver-selective activator group [RR＝2.26， 95%CI（1.02，5.03），

＝0.05] was higher than that in the control group， the difference was statistically significant.

CONCLUSIONS

Glucokinase activators can effectively reduce HbA

c， fasting blood glucose and 2 h postprandial blood glucose in patients with type 2 diabetes， but the risk of hypoglycemia remains to be addressed.

关键词

葡萄糖激酶激活剂2型糖尿病Meta分析有效性安全性

Keywords

type 2 diabetes mellitusmeta-analysisefficacysafety

references

中华医学会糖尿病学分会.中国2型糖尿病防治指南：2020年版[J].中华糖尿病杂志，2021，13（4）：315-409.

American Diabetes Association. Standards of medical care in diabetes：2022[J]. Diabetes Care，2022，45（Suppl 1）：S1-S264.

MANNUCCI E，CANDIDO R，MONACHE L D，et al. Italian guidelines for the treatment of type 2 diabetes[J]. Acta Diabetol，2022，59（5）：579-622.

STARK CASAGRANDE S，FRADKIN J E，SAYDAH S H，et al. The prevalence of meeting A1C，blood pressure，and LDL goals among people with diabetes，1988-2010[J]. Diabetes Care，2013，36（8）：2271-2279.

GRIMSBY J，SARABU R，CORBETT W L，et al. Allosteric activators of glucokinase：potential role in diabetes therapy[J]. Science，2003，301（5631）：370-373.

HAEUSLER R A，CAMASTRA S，ASTIARRAGA B，et al. Decreased expression of hepatic glucokinase in type 2 diabetes[J]. Mol Metab，2015，4（3）：222-226.

PERREAULT L，FAERCH K，KEREGE A A，et al. Hepatic glucose sensing is impaired，but can be normalized，in people with impaired fasting glucose[J]. J Clin Endocrinol Metab，2014，99（7）：E1154-E1162.

AMIN N B，AGGARWAL N，PALL D，et al. Two dose-ranging studies with PF-04937319，a systemic partial activator of glucokinase，as add-on therapy to metformin in adults with type 2 diabetes[J]. Diabetes Obes Metab，2015，17（8）：751-759.

KIYOSUE A，HAYASHI N，KOMORI H，et al. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab，2013，15（10）：923-930.

LIU D Y，DU Y，YAO X T，et al. Safety，tolerability，pharmacokinetics，and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes：a randomised controlled，crossover，single-centre phase 1 trial[J]. eClinicalMedicine，2021，42：101185.

MEININGER G E，SCOTT R，ALBA M，et al. Effects of MK-0941，a novel glucokinase activator，on glycemic control in insulin-treated patients with type 2 diabetes[J]. Diabetes Care，2011，34（12）：2560-2566.

MORROW L A，LEONSSON-ZACHRISSON M，ERICSSON H，et al. Safety，pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab，2012，14（12）：1114-1122.

VELLA A，FREEMAN J L R，DUNN I，et al. Targeting hepatic glucokinase to treat diabetes with TTP399，a hepatoselective glucokinase activator[J]. Sci Transl Med，2019，11（475）：eaau3441.

WILDING J P，LEONSSON-ZACHRISSON M，WESSMAN C，et al. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin[J]. Diabetes Obes Metab，2013，15（8）：750-759.

ZHENG S，SHAO F，DING Y，et al. Safety，pharmacokinetics，and pharmacodynamics of globalagliatin，a glucokinase activator，in Chinese patients with type 2 diabetes mellitus：a randomized，phase Ⅰb，28-day ascending dose study[J]. Clin Drug Investig，2020，40（12）：1155-1166.

ZHU D L，GAN S L，LIU Y，et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes：a dose-ranging，randomised，double-blind，placebo-controlled，phase 2 study[J]. Lancet Diabetes Endocrinol，2018，6（8）：627-636.

华领医药.华领医药糖尿病首创新药多格列艾汀NDA获NMPA受理！为全球首个葡萄糖激酶激活剂[EB/OL]. （2021-04-23）[2022-04-25]. https：//www.huamedicine.com/news-125.htmlhttps://www.huamedicine.com/news-125.html.

FILIPSKI K J，PFEFFERKORN J A. A patent review of glucokinase activators and disruptors of the glucokinase：glucokinase regulatory protein interaction：2011-2014[J]. Expert Opin Ther Pat，2014，24（8）：875-891.

TOULIS K A，NIRANTHARAKUMAR K，POURZITAKI C，et al. Glucokinase activators for type 2 diabetes：challenges and future developments[J]. Drugs，2020，80（5）：467-475.

ZHANG Q，RAMRACHEYA R，LAHMANN C，et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes[J]. Cell Metab，2013，18（6）：871-882.

LIU S P，AMMIRATI M J，SONG X，et al. Insights into mechanism of glucokinase activation：observation of multiple distinct protein conformations[J]. J Biol Chem，2012，287（17）：13598-13610.

BORZILLERI K A，PFEFFERKORN J A，GUZMAN-PEREZ A，et al. Optimizing glucokinase activator binding kinetics to lower in vivo hypoglycemia risk[J]. Med Chem Commun，2014，5（6）：802-807.

ZHU D，LI X，MA J，et al. Dorzagliatin in drug-naïve patients with type 2 diabetes：a randomized，double-blind，placebo-controlled phase 3 trial[J]. Nat Med，2022，28（5）：965-973.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of levetiracetam versus valproic acid in the treatment of pediatric epilepsy： a meta analysis

Efficacy and safety of kidney-tonifying Chinese patent medicine combined with PDE5 inhibitor in the treatment of erectile dysfunction：a network meta-analysis

Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy

Efficacy and safety of aerosol inhalation of polycolistin B in patients with severe pneumonia combined with mechanical ventilation

Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer

Related Author

LI Rui

LIU Chang

XU Lujie

LIU Lu

YAN Meixing

WANG Zhen

ZHANG Lijuan

LI Xujie

Related Institution

Dept. of Pharmacy， Qingdao Women and Children’s Hospital

School of Medicine and Pharmacy， Ocean University of China

Dept. of Chinese Osteo-traumatology， Neck， Shoulder， Waist and Leg Pain Hospital Affiliated to Shandong First Medical University

Dept. of Traditional Chinese Medicine， the Affiliated Hospital of Shandong University of Traditional Chinese Medicine

College of Acupuncture and Massage， Shandong University of Traditional Chinese Medicine

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰